Sullivan Eddie Joe 4

What Happened

• Eddie Sullivan, President and a director of SAB Biotherapeutics (SABS), was granted derivative awards on Feb 3, 2026: options covering 3,000,000 shares of common stock. The filing reports the acquisition price as $0.00 (award/grant); the transaction is reported as a derivative security rather than an immediate purchase or sale.

Key Details

• Transaction date: 2026-02-03; Form 4 filed: 2026-02-05 (appears timely).
• Transaction code: A (award/grant of derivative securities).
• Quantity: options to acquire 3,000,000 shares; reported transaction amount $0.00.
• Plan: Award issued under the Issuer’s 2021 Omnibus Equity Incentive Plan, as amended (Footnote F1).
• Vesting (Footnote F2): 1/4 vests on the one-year anniversary of the grant; remaining 3/4 vest pro rata monthly over the next 36 months (four-year total vesting).
• Shares owned after transaction: not provided in the supplied filing summary.

Context

• This was a compensation grant (options), not an open-market buy or sale. The options give the right to buy shares in the future subject to vesting; they are not immediately tradable shares. Such grants are common executive compensation to align management with long-term shareholder value and do not by themselves indicate a near-term purchase or sale of stock.